Viatris to Acquire Pacira Biosciences for $1.65 Billion
6 reports, 6 independent
Updated Sun 00:00
No new developments lately
Reached 4 outlets in its first 24 hours
- Reports
- 6
- Developments
- 4
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Viatris agreed to acquire Pacira Biosciences for an aggregate equity value of $1.65 billion, which equates to $36.50 per share for Pacira shareholders. The acquisition includes Pacira's commercial products and intellectual property related to non-opioid therapeutics, as well as its drug pipeline.
Why it matters
The deal allows Viatris to expand its portfolio with established, on-market therapies, including Exparel and Zilretta, which treat post-surgical and osteoarthritic pain. Separately, Ademi LLP is investigating whether the proposed acquisition provides fair value to Pacira's public shareholders.
From investors.com, prnewswire.com
Who's involved
How it developed
Newest first. Tap a step to see who reported it.Vitaris confirmed the acquisition of Pacira, including its commercial product line.1 source
Viatris plans to buy Pacira Biosciences, expanding its portfolio with Exparel.1 source
Ademi LLP is investigating the deal price for Viatris's proposed acquisition of Pacira.1 source
Viatris agreed to acquire Pacira BioSciences for $36.50 per share.1 source
Keep exploring
The entities involved
-
Mylan
former pharmaceutical company